Protein C pathway in sepsis

References

• Esmon CT. Protein C, protein S, and thrombomodulin. In: Colman WW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th edn. Philadelphia: Lippincott Williams Hc Wilkins; 2001: 335–53.
   Google Scholar
• Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin com-plex. Proc Nat! Acad Sci USA 1996; 93: 10212–6.
   PubMed Web of Science ®Google Scholar
• Laszik Z, Mitro A, Taylor FB, Jr., Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway. Circulation 1997; 96: 3633–40.
   PubMed Web of Science ®Google Scholar
• Liaw PCY, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 275: 5447–52.
   PubMed Web of Science ®Google Scholar
• Shu F, Kobayashi H, Fukudome K, Tsuneyoshi N, Kimoto M, Terao T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 2000; 477: 208–12.
   PubMed Web of Science ®Google Scholar
• Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880–2.
   PubMed Web of Science ®Google Scholar
• Grey S, Hau H, Salem HH, Hancock WW. Selective effects of protein C on activation of human monocytes by lipopoly-saccharide, interferon-gamma, or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc 1993; 25: 2913–4.
   PubMedGoogle Scholar
• Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199–203.
   PubMed Web of Science ®Google Scholar
• Heeb MJ, Gruber A, Griffin JH Identification of divalent metal ion-dependent inhibition of activated protein C by alphaa-macroglobulin and alphaz-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 1991; 266: 17606–12.
   PubMed Web of Science ®Google Scholar
• Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340–8.
   PubMed Web of Science ®Google Scholar
• Stenflo J. The biochemistry of protein C. In: Bertina RM, ed. Protein C and related proteins. London: Churchill-Living-stone; 1988: 21–54.
   Google Scholar
• Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the Gla domain of protein C. J Biol Chem 1997; 272: 26279–84.
   PubMedGoogle Scholar
• Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombo-modulin complex. J Biol Chem 1995; 270: 25336–9.
   PubMedGoogle Scholar
• Bourin MC, Lindahl U. Olycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313–30.
   PubMed Web of Science ®Google Scholar
• Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567–70.
   PubMed Web of Science ®Google Scholar
• Bajzar L, Morser J, Nesheim M. TAFI, or Plasma Procar-boxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603–8.
   PubMed Web of Science ®Google Scholar
• Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol lmmunol 2002; 46: 131–4.
   PubMed Web of Science ®Google Scholar
• Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162–7.
   PubMed Web of Science ®Google Scholar
• Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, et at Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002; 61: 490–501.
   PubMedGoogle Scholar
• Kurosawa S, Esmon CT, Stearns-Kurosawa DJ The soluble endothelial protein C receptor binds to activated neutrophils: Involvement of proteinase-3 and CDIIb/CDI8. J Immunol 2000; 165: 4697–703.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, et at. The endothelial cell protein C receptor aids in host defense against Escherichia colt sepsis. Blood 2000; 95: 1680–6.
   PubMed Web of Science ®Google Scholar
• Ogariesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NIL, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002; 277: 24851–4.
   PubMedGoogle Scholar
• Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, et al. Lipid antigen presentation in the immune system learned from CD1d knockout mice. Immunol Rev 1999; 169: 31–44.
   PubMed Web of Science ®Google Scholar
• Moody DB, Ulrichs T, Mühlecker W, Young DC, Gurcha SS, Grant E, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000; 404: 884–8.
   PubMed Web of Science ®Google Scholar
• Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743–6.
   PubMed Web of Science ®Google Scholar
• Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249–52.
   PubMed Web of Science ®Google Scholar
• Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, et at. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565–8.
   PubMed Web of Science ®Google Scholar
• Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486–91.
   PubMed Web of Science ®Google Scholar
• Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588–92.
   PubMed Web of Science ®Google Scholar
• Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, et at Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 1992; 90: 2565–73.
   PubMed Web of Science ®Google Scholar
• Takano 5, Kimura 5, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024–9.
   PubMed Web of Science ®Google Scholar
• Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracel-lular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995; 60: 1525–32.
   PubMed Web of Science ®Google Scholar
• Yuksel M, Uchiba M, Okajima K, Okabe H. Activated protein C inhibits LPS-induced production of TNF-alpha by monocytes through inhibition of activation of NF-kappaB and MAPK pathways. Thromb Haemost 2001; (Suppl. July): P508.
   Google Scholar
• Taoka Y, Okajima K, Uchiba M, Murakamt K, Harada N, Johno M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci 1998; 18: 1393–8.
   PubMed Web of Science ®Google Scholar
• White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, et al. Activated protein C inhibits lipopolysac-charide-induced nuclear translocation of nuclear factor kap-paB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110: 130–4.
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994; 4: 77–83.
   PubMed Web of Science ®Google Scholar
• Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982; 70: 127–34.
   PubMedGoogle Scholar
• Beller-Todd BK, Archer LT, Hinshaw LB. Recovery from endotoxin shock after extracorporeal perfusion without antic-oagulation. Circ Shock 1997; 6: 261–9.
   Google Scholar
• Taylor FB, Jr., Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res 1984; 36: 177–85.
   PubMedGoogle Scholar
• Taylor FB, Jr., Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987; 79: 918–25.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Jr., Esmon CT. Treatment of dysfunctional vascular endothelium using activated protein C. U.S. Patent No. 5,009,889; 1991.
   Google Scholar
• Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, et al. c4h-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78: 357–63.
   PubMed Web of Science ®Google Scholar
• Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197–202.
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49–56.
   PubMed Web of Science ®Google Scholar
• Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408–16.
   PubMed Web of Science ®Google Scholar
• Liaw PCY, Ferrell GL, Loeb M, Foley R, Weitz JI, Esmon CT. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2001; 98: 445.
   Google Scholar
• Hasegawa N, Kandra TG, Husari AW, Veiss S, Hart WT, Hedgpeth J, et al. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system or-gan failure in rats. Am J Respir Crit Care Med 1996; 153: 1831–7.
   PubMedGoogle Scholar
• Manqama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 718–21.
   PubMedGoogle Scholar
• Taoka Y, Okajima K, Uchiba M, Johno M. Neuroprotection by recombinant thrombomodulin. Thromb Haemost 2000; 83: 462–8.
   PubMed Web of Science ®Google Scholar
• Dreyfus M, Masterson M, David M, Rivard GE, Muller FM, Kreuz W, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995; 21: 371–81.
   PubMed Web of Science ®Google Scholar
• White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719–24.
   PubMed Web of Science ®Google Scholar
• Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126: 646–52.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.
   PubMed Web of Science ®Google Scholar